他汀类药物和体外膜肺氧合装置植入后血液相容性不良事件的关系

摘要
图/表
参考文献(26)
相关文章 (2)

全文: PDF (600 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探索心源性休克（PCS）患者植入体外膜肺氧合装置（ECMO）术后服用他汀类药物与早期发生血液相容性相关不良事件（HRAEs）的关系。方法收集2008年2月至2016年4月中国医学科学院阜外医院280例接受ECMO植入患者的临床资料，观察患者服用他汀类药物后HRAEs的发生情况，同时记录患者基本特征、并发症和其他用药情况。采用COX比例风险比回归等方法进行他汀类药物对HRAEs的影响研究，并采用倾向性评分进行匹配后再进行分析。结果非他汀组共212例，他汀组68例，分别有40例（18.87%）和17例（25.00%）发生HRAEs。Log-rank检验发现他汀组患者更易发生HRAEs（P = 0.014），他汀组出血事件的发生率高于非他汀组（P ＜ 0.05）。多因素分析发现他汀类药物可能是HRAEs发生的危险因素[HR（95%CI）=2.149(1.100～4.201)，P = 0.025]。利用倾向性评分进行匹配后，发现相对于未服用他汀类药物的患者，服用他汀类药物的患者更易发生HRAEs（P = 0.008）。结论 PCS患者植入ECMO后60 d内服用他汀类药物可能更易发生HRAEs，研究结果还需大样本研究验证。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	雷白侯剑峰胡盛寿

关键词 ：体外膜肺氧合装置, 血液相容性不良事件, 血液相容性评分, 他汀类药物

Abstract：Objective To explore the relationship of hemocompatibility related clinical adverse events (HRAEs) and statin treatment after extra-corporeal membrane oxygenation (ECMO) implantation in patients with postoperative cardiac shock (PCS). Methods Clinical data of 280 patients who received ECMO implantation in Fuwai Hospital, Peking Union Medical College from February 2008 to April 2016 were collected to observe the occurrence of HRAEs after taking statins, and the basic characteristics, complications and other medication of patients were recorded. COX proportional hazard ratio regression and other methods were used to study the effect of statins on HRAEs, and propensity score was used for matching and re-analysis. Results HRAEs occurred in 40 (18.87%) and 17 (25.00%) patients in the non-statin group and 68 patients in the statin group, respectively. Log-rank test showed that patients taking statins were more likely to develop HRAEs (P = 0.014), and the incidence of bleeding events was higher in the statin group than in the non-statin group (P ＜ 0.05). Multivariate analysis showed that statins may be a risk factor for HRAEs [HR (95%CI) =2.149(1.100-4.201), P = 0.025]. After matching using a propensity score, HRAEs were more common in patients taking statins than in those not taking statins (P = 0.008). Conclusion PCS patients are prone to HRAEs with statins after ECMO implantation in 60 days. The results need to be verified by large sample studies.

Key words： Extra-Corporeal Membrane Oxygenation Hemocompatibility related clinical adverse events Hemocompatibility score Statins

基金资助:国家重点研发计划重点专项项目（2016YFC13009 00）。

通讯作者: 胡盛寿（1956-），男，教授，院士；研究方向：心血管外科以及心室辅助装置。

作者简介: 雷白（1985-），男，博士；研究方向：心血管外科疾病和心室辅助装置。

引用本文:

雷白侯剑峰胡盛寿. 他汀类药物和体外膜肺氧合装置植入后血液相容性不良事件的关系[J]. 中国医药导报, 2021, 18(32): 66-70.
LEI Bai HOU Jianfeng HU Shengshou. Relationship between statins and hemocompatibility related clinical adverse events after extra-corporeal membrane oxygenation implantation#br#. 中国医药导报, 2021, 18(32): 66-70.

链接本文:

https://www.yiyaodaobao.com.cn/CN/ 或 https://www.yiyaodaobao.com.cn/CN/Y2021/V18/I32/66

[1] Mehra MR. The burden of haemocompatibility with left ventricular assist systems：a complex weave [J]. Eur Heart J，2019，40（8）：673-677.
[2] Chung M，Cabezas FR，Cabezas JI，et al. Hemocompatibility-Related Adverse Events and Survival on Venoarterial Extracorporeal Life Support：An ELSO Registry Analysis [J]. JACC Heart Fail，2020，8（11）：892-902.
[3] Mehra MR，Naka Y，Uriel N，et al. A fully magnetically levitated circulatory pump for advanced heart failure [J]. N Engl J Med，2017，376（5）：440-450.
[4] Imamura T，Nguyen A，Kim G，et al. Optimal haemodynamics during left ventricular assist device support are associated with reduced haemocompatibility-related adverse events [J]. Eur J Heart Fail，2019，21（5）：655-662.
[5] Willey JZ，Gavalas MV，Trinh PN，et al. Colombo PC. Outcomes after stroke complicating left ventricular assist device [J]. J Heart Lung Transplant，2016，35（8）：1003-1009.
[6] Roever L，Resende ES，Mehra MR. Vulnerable Brain and Ventricular Assist Devices [J]. Stroke，2016，47：2677-2678.
[7] Rogers JG，Pagani FD，Tatooles AJ，et al. Intrapericardial left ventricular assist device for advanced heart failure[J]. N Engl J Med，2017，376（5）：451-460.
[8] Mandeep MR，Sundareswaran KS，Uriel N. Response by Mehra to Letter Regarding Article，“ Hemocompatibility-Related Outcomes in the MOMENTUM 3 Trial at 6 Months：A Randomized Controlled Study of a Fully Magnetically Levitated Pump in Advanced Heart Failure” [J].Circulation，2017，136（19）：1872-1873.
[9] Mehta P，Imamura T，Belkin M，et al. Neurohormonal blockade reduces adverse events during LVAD support [J]. J Heart Lung Transplant，2018，37（4）：180-181.
[10] 侯剑峰，陈凯.体外膜肺氧合与主动脉球囊反搏联合辅助救治心血管外科术后心原性休克：阜外医院单中心十一年经验总结[J].中国循环杂志，2019，34（1）：66-71.
[11] Maltais S，Kilic A，Nathan S，et al. Prevention of Heart Mate Ⅱ pump thrombosis through clinical management：the PREVENT multi-center study [J]. J Heart LungTransplant，2017，36（1）：1-12.
[12] Sparrow CT，Nassif ME，Raymer DS，et al. Preoperative right ventricular dysfunction Is associated with gastrointestinal bleeding in patients supported with continuous-flow left ventricular assist devices [J]. JACC Heart Fail，2015，3（12）：956-964.
[13] 中国医师协会体外生命支持专业委员会．成人体外膜氧合循环辅助专家共识[J]．中华医学杂志，2018，98（12）：886-894．
[14] Li B，Sun G，Cheng Z，et al. Analysis of nosocomial infections in post-cardiac surgery extracorporeal membrane oxygenation support therapy [J]. Heart Surg Forum，2018， 21（5）：E387-E391.
[15] 侯剑峰，陈凯.体外膜肺氧合救治心血管术后心原性休克患者的研究[J].中国循环杂志，2019，34（5）：492-497.
[16] 陈虹.高脂血症与血液流变学部分指标的关系[J].中国疗养医学，2012，21（12）：1151-1152．
[17] Wang C，Zhang L，Qin T，et al. Extracorporeal membrane oxygenation in trauma patients：a systematic review[J]. World J Emerg Surg，2020，15（1）：1-14.
[18] Menaker J，Galvagno S，Rabinowitz R，et al. Epidemiology of blood stream infection in adult extracorporeal membrane oxygenation patients：a cohort study [J]. Heart Lung，2019，48（3）：236-239.
[19] Imamura T，Nguyen A，Rodgers D，et al. Omega-3 therapy is associated with reduced gastrointestinal bleeding in patients with continuous-flow left ventricular assist device [J]. Circ Heart Fail，2018，11（10）：e005082.
[20] Nakamura M，Imamura T，Hori M，et al. Regulation of angiopoietin-2 before and after mechanical circulatory support therapy [J]. Asaio J，2021，67（1）：53-58.
[21] Thomas J，Kostousov V，Teruya J. Bleeding and thrombotic complications in the use of extracorporeal membrane oxygenation [J]. Semin Thromb Hemost，2018，44（1）：20-29.
[22] Sandner SE，Zimpfer D，Zrunek P，et al. Age and outcome after continuous flow left ventricular assist device as a bridge to transplantation[J]. J Heart Lung Transplant，2009，28：367-372.
[23] Sandner SE，Nolz R，Loewe C，et al. Routine preoperative aortic computed tomography angiography is associated with reduced risk of stroke in coronary artery bypass grafting：a propensity-matched analysis [J]. Eur J Cardiothorac Surg，2020，57（4）：684-690.
[24] Lang NW，Schwihla I，Weihs V，et al. Survival rate and outcome of extracorporeal life support （ECLS） for treatment of acute cardiorespiratory failure in trauma patients [J]. Sci Reports 2019，9（1）：1-6.
[25] Lushaj EB，Badami A，Osaki E，et al. Impact of age on outcomes following continuous flow left ventricular assist device implantation [J]. Interact Cardiovasc Thorac Surg，2015，20：743-748.
[26] Lushaj EB，Bartlett HL，Lamers LJ，et al. Technical Performance Score Predicts Perioperative Outcomes in Complex Congenital Heart Surgery Performed in a Small-to-Medium-Volume Program [J]. Pediatr Cardiol，2020，41（1）：88-93.